Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Access of Momelotinib for Myelofibrosis
2017-004350-42Phase 2Active
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF), sponsored by GSK. Primary endpoint: Safety. Started Apr 2018; status: active.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2017-004350-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004350-42.